Huadong Medicine Co., Ltd (SHE: 000963) announced that China’s National Medical Products Administration (NMPA) has approved a clinical study for DR30206, a Category 1 therapeutic biologic, in combination with standard therapy for locally advanced or metastatic non‑small cell lung cancer (NSCLC). The triple‑target fusion protein—targeting PD‑L1, VEGF, and TGF‑β—advances into Phase II development following its initial IND clearance for advanced solid tumors in June 2023.
Regulatory Milestone
Item
Detail
Company
Huadong Medicine Co., Ltd (SHE: 000963)
Product
DR30206
Drug Class
Category 1 therapeutic biologic; fusion protein
Targets
PD‑L1 + VEGF + TGF‑β (triple‑target)
Regulatory Action
NMPA clinical study approval
Indication
Locally advanced or metastatic NSCLC (combination with standard therapy)
Triple‑Target Differentiation: DR30206’s simultaneous PD‑L1/VEGF/TGF‑β blockade represents a next‑generation immuno‑oncology approach, potentially superior to dual‑target bispecifics (e.g., PD‑1/VEGF) by addressing TGF‑β‑mediated immunosuppression—a key resistance mechanism in NSCLC.
NSCLC Market Positioning: Targeting locally advanced/metastatic NSCLC—the largest cancer indication globally—with standard therapy combination positions DR30206 for front‑line or second‑line use, competing with pembrolizumab, atezolizumab, and emerging bispecifics.
Fusion Protein Advantage:Single‑molecule triple targeting ensures coordinated pharmacokinetics and simplified manufacturing vs. combination regimens requiring multiple agents, potentially improving patient compliance and cost‑effectiveness.
Huadong Innovation Pipeline:Category 1 biologic status demonstrates Huadong’s transition from traditional pharma (generics, APIs) to innovative biologics, supporting valuation re‑rating and partnership attractiveness.
Ivonescimab (Akeso), AK112 (Akeso) gaining traction; DR30206’s TGF‑β addition may differentiate in TGF‑β‑high tumor microenvironments
China Biologics Innovation
NMPA’s rapid approval of complex fusion proteins signals regulatory maturity; Huadong joins leading domestic immuno‑oncology developers
Forward‑Looking Statements This brief contains forward‑looking statements regarding Phase II enrollment, combination safety profile, and efficacy outcomes for DR30206 in NSCLC. Actual results may differ due to risks including triple‑target toxicity, competitive bispecific launches, and manufacturing complexity for fusion proteins.-Fineline Info & Tech
By Fineline Cube